Registration Dossier
Registration Dossier
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 203-808-3 | CAS number: 110-85-0
Endpoint summary
Administrative data
Description of key information
Two dietary 90 -day studies are available, one in rats and one in dogs.
Key value for chemical safety assessment
- Toxic effect type:
- dose-dependent
Repeated dose toxicity: via oral route - systemic effects
Endpoint conclusion
- Endpoint conclusion:
- adverse effect observed
- Dose descriptor:
- NOAEL
- 627 mg/kg bw/day
- Study duration:
- subchronic
- Species:
- rat
Repeated dose toxicity: inhalation - systemic effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
Repeated dose toxicity: dermal - systemic effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
Additional information
In a subchronic study in rats, a NOAEL of 627 mg piperazine base/kg bw/day has been established based on reduced body weight gain observed at the next higher level tested. In a subchronic study in dogs the NOAEL was set at the highest level tested as no treatment-related changes were observed; this NOAEL was at least 25 mg piperazine base/kg bw/day during the first 5 weeks of the study, and at least 60 mg/kg bw/day during week 6 -13 of the study.
Justification for classification or non-classification
In view of the NOAEL of 627 mg piperazine base/kg bw/day in rats and the NOAEL of at least 25/60 mg piperazine base/kg bw/day in dogs in 90 -day studies, there is no need to classify piperazine for STOT Repeated Exposure.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
